AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00026312 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00026312 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04548804 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ECG-Imaging
Description: A body surface potential mapping and a cardiac + low dose CT-scan
Study NCT03719313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG IFN-alfa-2a
Description: PEG IFN alfa-2a 180 mcg QW
Study NCT00026312 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00026312 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01566383 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 24-hr pH monitoring
Description: Visit 1~The following will be done:~* A medical history including review of your current drugs;~* Collection of demographic information;~* A manometry, before the 24-hour pH testing, to find the junction between the esophagus and stomach;~* 24-hour pH testing will be done~Visit 2~You will return to the clinic 24 hours after the visit 1 and the following will occur:~* The catheter will be removed from your nose; and~* You will return the recording device
Study NCT00608959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omiganan 1% gel
Description: Omiganan 1% gel will be applied to 6 sites on the chest and/or abdomen.Swab cultures will be obtained at specified timepoints over a period of 3 days (Part1) or 7 days (Part 2).~In addition, subjects in Part 2 will have omiganan 1% gel applied to one intravenous (IV) catheter site.
Study NCT00608959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine 2% solution
Description: Part 1- chlorhexidine 2% solution will be applied to 6 sites on the chest and/or abdomen. All application sites will be covered with semi-transparent dressings.Swab cultures will be obtained at specific timepoints over a period of 3 days.~Part 2: Subjects in Part 2 will have chlorhexidine 2% solution applied to one intravenous (IV) catheter site only.
Study NCT03206398 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: anti-gravity treadmill
Description: anti-gravity treadmill for a total of 40 days in addition to physiotherapy
Study NCT02198105 — intervention group
Intervention type: DEVICE
Intervention: Cutting-Balloon-PTA (VascuTrak) and Drug Coated Ballon PTA
Description: Interventional procedure:~1. PTA with Cutting-Balloon (60-120 seconds).~2. PTA with DC-Balloon (60 seconds).~Technical success is defined as~1. no recoil >30%~2. no dissection >Type B~3. no stenting >30% of lesion length.
Study NCT01933776 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap
Description: 0.5 mL, Intramuscular (IM)
Study NCT00026312 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00026312 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00026312 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given IV or SC
Study NCT04218318 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: phototherapy
Description: Phototherapy will be commenced for neonates in both groups according to AAP guidelines.Neonates will be treated with intensified overhead blue LEDs phototherapy if they have a TSB level at or above phototherapy threshold. Neonates will be started on intensified 360◦ LED phototherapy if they have TSB level within 50µmol/L below the exchange threshold. The administration of IVIG is indicated in infants with isoimmune hemolytic disease if TSB lies within 34 to 51 micromol/L of the threshold for exchange transfusion and not responding to initial intensified phototherapy.Infants with a TSB concentration above the thresholds for exchange should have immediate intensified 360◦ LED phototherapy, and preparation for exchange transfusion will be started.Infants showed clinical signs of acute bilirubin encephalopathy will have an immediate exchange transfusion.
Study NCT04542616 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation
Description: Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation for the treatment of severe uncontrolled glaucoma.
Study NCT02681692 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic endoscopic imaging system
Description: In the first part,patients would be randomly assigned to have colonoscopy examination performed by one inexperienced colonoscopist (having performed less than 200 procedures) with the assistance of magnetic scope navigation system In the second part colonoscopist would be randomized to perform conventional colonoscopy on a colon model with an MEI view while the force measurement device being used to collect data of colon force variation meanwhile. No patients would be involved in this part. All force variation data would be recorded by a image storage device.
Study NCT04142697 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Heading direction adaptation
Description: Will adapt subject's perceived heading direction using exposure to visual environments that include rotation and situations where visual and inertial heading direction are systematically offset.
Study NCT03569241 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: whole pelvic radiotherapy
Description: addition of prophylactic whole pelvic radiotherapy to a local metastasis-directed treatment
Study NCT03569241 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: metastasis-directed treatment
Description: stereotactic body radiotherapy
Study NCT03569241 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: metastasis-directed treatment
Description: stereotactic body radiotherapy
Study NCT03569241 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: salvage Lymph Node Dissection
Description: metastasis-directed treatment
Study NCT03569241 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: salvage Lymph Node Dissection
Description: metastasis-directed treatment
Study NCT03569241 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: androgen deprivation therapy
Description: LHRH-agonist (+ anti-androgen) or antagonist for a duration of 6 months
Study NCT03569241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: androgen deprivation therapy
Description: LHRH-agonist (+ anti-androgen) or antagonist for a duration of 6 months
Study NCT04511533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Description: Dacomitinib is a kinase inhibitor indicated for the first line treatment of patients with metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations.
Study NCT05150392 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational live attenuated varicella vaccine
Description: The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.And the live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection
Study NCT01546909 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria, tetanus, polio and pertussis vaccination
Description: 1 dose of TETRAVAC-ACELLULAIRE (0.5 mL) at Day 0
Study NCT02146911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Study NCT02146911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Study NCT02146911 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly Motivational Emails
Description: The e-mails will include tips on several things other than the medications that participants can do to help them quit smoking. The contents of the emails will vary from week to week. The e-mails will provide tips on ways to create an atmosphere that promotes quitting and staying abstinence. They will also include recommendations on how to address issues with withdrawal symptoms and cravings. In addition, they will provide positive motivational messages by stating facts on benefits of quitting smoking.
Study NCT04409262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remdesivir
Description: Participants will receive intravenous (IV) RDV
Study NCT04409262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Participants will receive intravenous (IV) RDV
Study NCT04409262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV TCZ
Study NCT02390947 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 25 mg p.o. qd
Study NCT04006002 — intervention group
Intervention type: OTHER
Intervention: Metabolic and Hormonal profile
Description: To assess changes in metabolic profiles and body metrics such as weight and BMI in these patients after an endoscopic or surgical bariatric intervention
Study NCT01459783 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dementia care management
Description: Care management is initiated via a structured assessment, to identify prevalent caregiving problems: unmet need for assistance, lack of social support, educational needs, difficulty with managing behavioral issues and safety concerns, need for respite, establishing advance care planning, depression of the person with dementia as well as the caregiver, management of other chronic medical issues, and need for diagnostic information and assistance with acute medical issues. Collaboration between the caregiver and the care manager results in problem prioritization and subsequent counseling, education, referrals as needed, and proactive follow-up to achieve resolution of these problems. An electronic tracking tool and resource manual guide delivery of the care management protocols.
Study NCT03435471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prophylactic Swallowing Home Exercise Program
Description: The home exercise program will consist of six exercises that are recommended to be practiced three times per day. Subjects will complete a weekly exercise log to track compliance.
Study NCT04269356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986256
Description: Specified dose on specified days
Study NCT04269356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milk of magnesia
Description: Specified dose on specified days
Study NCT01331109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran
Description: maximum tolerated dose (50, 75, or 100 mg/day tablets); for 52 weeks.
Study NCT00066963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluoride Varnish
Description: 0.1 mL (1 drop) applied on each of 2 arches
Study NCT04543292 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MATFILL (PTFE)
Description: Filling of the prosthetic chimney with the compressed material
Study NCT00988091 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1.2% Sodium Hyaluronate
Description: IA-BioHA is supplied in a disposable 7 ml nominal volume glass syringe containing 60 mg/5 ml of 1.2% sodium hyaluronate. Participants are given a single injection in the target knee on Day 1 of the double-blind period and optionally on the first day of the open-label period (approximately week 27).
Study NCT00988091 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Buffered Saline
Description: IA-SA is supplied in a disposable 7 ml nominal volume glass syringe containing 5 ml of phosphate buffered saline. Participants are given a single injection in the target knee on Day 1 of the double-blind period.
Study NCT01111344 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glizigen + Viusid
Description: Glizigen (spray, 60 mL bottle with applicator): Dosage commensurate with surface (up to a maximum of 10 cm2) to be treated. From 3 to 5 ambulatory applications (One nebulization corresponds to 2 short pulses).~* 1 to 3.9 cm2 ______________3 daily applications~* 4 to 6.9 cm2 ______________4 daily applications~* 7 to 10 cm2 ______________5 daily applications Treatment will last from 5 days to 8 weeks according to clinical improvement.~Viusid (Syrop, 500 mL flask): 12.5 ml every 8 hours for 12 weeks. Viusid syrop should be dissolved in water, fruit juice or milk before ingestion.
Study NCT01111344 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Glizipen (spray, 60 mL bottle with applicator): Dosage commensurate with surface (up to a maximum of 10 cm2) to be treated. From 3 to 5 ambulatory applications (One nebulization corresponds to 2 short pulses).~* 1 to 3.9 cm2 ______________3 daily applications~* 4 to 6.9 cm2 ______________4 daily applications~* 7 to 10 cm2 ______________5 daily applications Treatment will last from 5 days to 8 weeks according to clinical improvement.~Placebo Viusid (Syrop, 500 mL flask): 12.5 ml every 8 hours for 12 weeks. Viusid syrop should be dissolved in water, fruit juice or milk before ingestion.
Study NCT03719313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Lonafarnib
Description: Placebo
Study NCT03719313 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Lonafarnib
Description: Placebo
Study NCT03719313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Ritonavir
Description: Placebo
Study NCT03719313 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ritonavir
Description: Placebo
Study NCT00259090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg intramuscular injection
Study NCT00259090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrazole
Description: oral tablet
Study NCT00259090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrazole
Description: oral tablet
Study NCT01589757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Standard dietary advice for women with GDM with special emphasis on use of high fiber or whole grain carbohydrate foods with a medium to high GI. What's on Your Plate? and 3-dimensional food models will be used to teach servings size and meal planning. This groups will be provided with food substitution lists (key-foods method) composed of medium to high GI foods.
Study NCT01589757 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low GI diet
Description: Nutrition education according to standard care similar to the control group with supplementary GI-education. GI-education will be taught using the Stop-Light-Method. This groups will be provided with food substitution lists (key-foods method) composed of low-GI carbohydrate-containing food. The GI-education tool(s) will build on standard care education where patients are taught which food groups contain carbohydrate.
Study NCT01436812 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: zero end-expiratory pressure
Description: positive end expiratory pressure 0 cm H2O during peumoperitoneum
Study NCT01436812 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: positive end expiratory pressure
Description: PEEP 0 cmH2O
Study NCT02319005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Revusiran (ALN-TTRSC)
Study NCT02319005 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Normal Saline (0.9% NaCl)
Study NCT01194947 — intervention group
Intervention type: DEVICE
Intervention: RCM imaging
Description: RCM imaging will be performed using a commercially-available RCM (Vivascope 1500, Lucid Inc, Rochester, NY, USA) with 830-nm diode laser with emitting power less than 35 milliwatts
Study NCT00641095 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: concentrate for solution for infusion
Study NCT00641095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Tablets
Study NCT00641095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Tablets
Study NCT00641095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Film coated tablet
Study NCT00641095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Film coated tablet
Study NCT03435471 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic Swallowing Home Exercise Program
Description: The home exercise program will consist of six exercises that are recommended to be practiced three times per day. Subjects will complete a weekly exercise log to track compliance.
Study NCT03435471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinician-Directed Prophylactic Swallowing Exercises
Description: Once weekly face-to-face meetings with a study speech pathologist for a total of six sessions, to participate in active swallowing exercises
Study NCT03547895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir 400mg (Sovaldi) + Daclatasvir 60 mg (Daklinza) + Ribavirin 200 mg (Rebetol)
Description: sofosbuvir 400mg+ribavirin 400mg+daclatasvir 60 mg were adminstered for 3 months
Study NCT03547895 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vitamin K (Phytomenadione) 10 mg+ furosemide and spironolactone (Lasilactone) 50 mg + milk thistle (Silymarin) 140 mg + Albumin infusion
Description: symptomatic therapy for liver support, control of ascites and bleeding tendency.
Study NCT02465372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CSPAP
Description: Comprehensive School Physical Activity Program.
Study NCT00281346 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Doppler echocardiography
Description: Echocardiography
Study NCT02113033 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Equilia® Vagal Nerve Stimulation
Description: Vagal Nerve Stimulation synchronized with cardiac activity
Study NCT03637478 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Systems of Care Team
Description: E-SOC team will be increasing connections between clinical care and community partners, such as schools, juvenile justice and child-serving state agencies, to reduce disparities in access to mental health/substance use evaluation and treatment. All aspects of the care continuum will be provided in a culturally and linguistically competent manner, with child and family-driven care planning. Overall goals are: earlier identification of mental health needs including child trauma; increased treatment access and adherence; care delivered in least restrictive settings; care experience reflecting active youth and family engagement; program sustainability and replicability.
Study NCT04583332 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Rhymes
Description: Participants will be provided with a choice of 3 Nursery rhymes (Wheels on the bus, Old McDonald and Twinkle Twinkle Little Star) Objects pertaining to the 3 rhymes will be placed on a board Children will be given prompts as per their need and will be marked on the type of prompt given.~These children will transit to pictures and Makaton symbols, if they are able to make choices using objects.
Study NCT04583332 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Individual Items in Rhymes
Description: Participants will be provided with a choice of 3 pictures within the initial choice making of the 2 Nursery rhymes (Wheels on the bus and Old McDonald ) Wheels on the Bus will include - mama/wipers/horn McDonalds - cow/dog/cat Objects pertaining to the 3 rhymes will be placed on a board Children will be given prompts as per their need and will be marked on the type of prompt given.~These children will transit to pictures and Makaton symbols, if they are able to make choices using objects.
Study NCT04583332 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Objects
Description: Participants will be provided with 2,3 and 4 sensory objects. Participants will opt for an object by making a choice between these objects, if this is achieved then the child will be moved to picture level and symbol.
Study NCT03165916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bard 5 Fr diameter feeding tube
Description: A pediatric feeding tube is used as a stent over which biliary anastomosis is performed. This is not a permanent stent and generally migrates out on its own.
Study NCT00545714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 250 mg/m\^2 as IV infusion will be administered on Days 1-3 of first six 28-day cycles.
Study NCT04152889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab, 200 mg solution intravenously for 30 min in first day every 3 weeks. Repeated every 21 days. 21 days for a cycle.
Study NCT04152889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Tegafur-gimeracil-oteracil potassium: 80 - 120 mg bid orally in 14 days, followed by 7 days off. Rrepeated every 21 days. 21 days for a cycle.
Study NCT04152889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel: 40 mg/m\^2 solution intravenously for 1 hour in first day every 3 weeks. Repeated every 21 days, 21 days for a cycle, from second cycle to seventh cycle.
Study NCT01702246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 40 mg, orally, once daily for 3 months
Study NCT04504383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN-943
Description: Administered by the oral route BID for the duration of the study.